Physician profile
Jason Calloway
NPI 1730728841
$3,501.02
in general payments reported to CMS, 2019-2025
22 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $887 · 2023: $1,922 · 2024: $417 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.84 |
| Education | $155.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $792.34 | 2022-2024 | Clik X |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $649.08 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $641.45 | 2023-2024 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $265.64 | 2023-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $139.59 | 2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.03 | 2023-2024 | Relistor |
| Forte Bio-Pharma LLC | $114.72 | 2022-2024 | Prolate, Nalocet |
| Nevro Corp. | $113.50 | 2022 | |
| Axsome Therapeutics, INC. | $92.60 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $83.30 | 2023 | Ingrezza |
| Abbvie INC. | $74.92 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $68.14 | 2023-2024 | Uzedy |
| Alkermes, INC. | $61.63 | 2023-2024 | Lybalvi, Aristada, Aristada Initio |
| Lundbeck LLC | $53.53 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $50.96 | 2023-2024 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $47.11 | 2025 | Dovato |
| Vanda Pharmaceuticals INC. | $25.76 | 2023 | Fanapt, Hetlioz |
| Relievant Medsystems, INC. | $24.97 | 2023 | Intracept |
| Itamar Medical INC | $23.06 | 2023 | Watchpatone |
| Nalu Medical, INC. | $22.78 | 2023 | Nalu Neurostimulation System |
| Daiichi Sankyo INC. | $22.50 | 2025 | Injectafer |
| Almatica Pharma LLC | $13.41 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Calloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.